Juan Barriuso-Navarro

Cerdanyola Del Valles, CT 08193, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis.

Journal: Biomedicines
Published: September 22, 2021

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Journal: Frontiers in immunology
Published: August 27, 2020

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Journal: BMJ open
Published: September 11, 2019

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.

Journal: Frontiers in immunology
Published: December 18, 2018

Comparison of dendritic cells obtained from autoimmunty-prone and resistant rats.

Comparison of dendritic cells obtained from autoimmunty-prone and resistant rats.

Journal: Immunobiology
Published: December 03, 2018

Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.

Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.

Journal: Mediators of inflammation
Published: October 31, 2018

Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.

Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.

Journal: CNS neuroscience & therapeutics
Published: October 29, 2018

Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.

Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.

Journal: Journal of neuroinflammation
Published: October 03, 2018

Ethyl Pyruvate Induces Tolerogenic Dendritic Cells.

Ethyl Pyruvate Induces Tolerogenic Dendritic Cells.

Journal: Frontiers in immunology
Published: September 27, 2018

Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin.

Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin.

Journal: Scientific reports
Published: July 16, 2018

Searching for the Transcriptomic Signature of Immune Tolerance Induction-Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages.

Searching for the Transcriptomic Signature of Immune Tolerance Induction-Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages.

Journal: Frontiers in immunology
Published: May 29, 2018

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Journal: CNS neuroscience & therapeutics
Published: November 01, 2017
Showing 1-12 of 16

Last Updated: 09/26/2026